The potential injection treatment -- which has shown promise in rodent models -- is a substantive breakthrough for HIV patients, said Howard Gendelman, M.D., professor and chairman of the department of pharmacology and experimental neuroscience, who leads the team that includes members from two UNMC colleges and two other universities.
|Howard Gendelman, M.D.|
The research is funded as a three-year, $4.6 million pilot grant from the National Institute on Drug Abuse at the National Institutes of Health.
In the first year, the research team has successfully developed a lead drug formulation in rodents. Tests are now underway in larger animals. Human use will require Food and Drug Administration (FDA) approval.